natgillin/translations-raw huggingface dataset:
Correct operation of comparing circuits 14a, 14b can thus be tested, and telegram transmission interrupted in the event the detected errors fail to match. 
Ispravan rad uspoređujućih komunikacijskih krugova 14a, 14b se tako može testirati i prekinuti prijenos telegrama u slučaju da izostane podudaranje detektiran ih grešaka.
An antibody according to any one of claims 1 to 8 or the immunoconjugate of any one of claims 10 to 12 for use in a method of treating a proliferative disorder, optionally in combination with an effective amount of another therapeutic agent. An antibody or immunoconjugate for use as a medicament according to claim 15, wherein said proliferative disorder is cancer, optionally lymphoma, non-Hodgkins lymphoma (NHL), diffuse large B-cell lymphoma, aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Protutijelo prema bilo kojem od zahtjeva 1 do 10, konjugat protutijelo-lijek prema bilo kojem od zahtjeva 16 do 39, ili farmaceutska formulacija prema zahtjevu 40, naznačen/o/a time, da se upotrebljava u postupku liječenja raka, pri čemu je poželjno rak odabran iz skupine koju čine: limfom, mijelom, non-Hodgkins-limfom (NHL), difuzni limfom velikih B-stanica, agresivni NHL, indolentni NHL, folikularni limfom, povratni agresivni NHL, povratni indolentni NHL, uporni NHL, uporni indolentni NHL, kronična limfocitna leukemija (CLL), limfom malih limfocita, leukemija, leukemija kosmatih stanica (HCL), akutna limfocitna leukemija (ALL) i limfom plaštenih stanica.
An immunogenic composition according to claim 9, further comprising at least a second staphylococcal antigen, wherein the second staphylococcal antigen is optionally selected from the group consisting of ClfA, EsaB, Emp, EsxA, EsxB, EsaC, Eap, Ebh, Coa, vWh, Hla, SdrC, SdrE, IsdA, IsdB, IsdC, ClfB, SasF peptide, a type V and/or a type VIII capsular polysaccharide or oligosaccharide from S. aureus. 
dva ili više segmenata D domene; ili neproteinski A segment, poželjno segment drugog antigena, naznačen time, što je segment drugog antigena opcionalno segment stafilokoknog antigena, poželjno Emp, EsxA, EsxB, EsaC, Eap, Ebh, EsaB, Coa, vWbp, vWh, Hla, SdrC, SdrD, SdrE, IsdA, IsdB, IsdC, ClfA, ClfB i/ili SasF segment.
A compound as defined in any one of claims 1-7, in free or salt form, for use as a pharmaceutical. 
Spoj kako je definiran u bilo kojem od zahtjeva 1 do 5, u slobodnom obliku ili obliku soli, za uporabu kao farmaceutik.
In some embodiments the dietary fibre preparation is derived from an edible Cactaceae plant belonging to the family Opuntioideae, more particularly to the genus Opuntia, and even more particularly to the species Opuntia ficus - indica . 
Pripravak za upotrebu prema zahtjevu 1 naznačen time da biljka kaktusovka pripada rodu Opuntia, na primjer, vrsti Opuntia ficus-indica, proizvoljno pri čemu je pripravak dijetalnih vlakana dobiven od kladodija biljke Opuntia ficus-indica.
The present invention is based in part on the recognition that carbohydrate derivatives of rapamycin in which the rapamycin molecule is modified at the 31- and/or 42- position, as defined by the current Chemical Abstracts nomenclature, by attaching monosaccharide(s), oligosaccharide(s) or pseudosugars, have similar or enhanced pharmacokinetic and/or pharmacodynamic profiles compared to rapamycin. 
Bit izuma Ovaj izum dijelom se temelji na činjenici da ugljikohidratni derivati rapamicina u kojima je molekula rapamicina modificirana na položajima 31 i/ili 42, kako je definirano važećom nomenklaturom po Chemical Abstracts, dodatkom monosaharida, oligosaharida ili pseudošećera, imaju sličan ili poboljšan farmakokinetički i/ili farmakodinamički profil u usporedbi s rapamicinom.
Secondary phases may include, for example, but are not limited to, alkali/alkaline earth sulfates, quartzes, spinels, olivines, pyroxenes, substances from the melilith and merwinite groups, apatites, ellestadites, silicocarnotite, free lime, spurrite, quartz and/or an X-ray amorphous phase content/a glassy phase, in a content of 0% by weight to 30% by weight, preferably 2% by weight to 20% by weight, and still more preferably 5% by weight to 15% by weight. 
Postupak sukladno barem jednom od zahtjeva 1 do 3, naznačen time što se vrsta 1 količina jedne ili više sekundarne faze kontrolira omjerima po težini CaO/AbO; (Fe,O3), CaO/SiO, i udjelom nosača sulfata u sirovoj mješavini materijala, pri čemu sekundarne faze, na primjer kalcijevi silikati, sulfati,kalcijevi aluminati, spineli, predstavnici melilite grupe, periklas, slobodno vapno, kvarca i / ili faze stakla, su prisutni u omjeru od 0.1 do 30 tež %, poželjno 5 do 20 tež % i poželjnije 10 do 15 tež %.
In other more specific embodiments of the foregoing, Q1 is: wherein: R2 is hydrogen; and R1 and R3 together with the atoms to which they are attached form a carbocyclic ring having from 4 to 6 ring atoms. 
Bi parna da iu din" MHRS pri čemu: R> je vodik; i R, i R3 zajedno s atomima za koje su vezani tvore karbociklički prsten koji ima od 4 do 6 atoma prstena. 11.
towards the center of gravity. 
prema središtu gravitacije.
the mixed mode chromatographic steps (a) and (b) recited in claim 1; and 
(2) -kromatografske korake (a) i (b) mješovitog načina iz zahtjeva 1; 1
and reacting the compound of formula VIII with a compound of formula IX in which R* is halogen, hydroxy or C1-6 alkoxy to the compound of formula I. 
i reakciju spoja s formulom VIII sa spojem s formulom IX [image] u kojoj R* je halogen, hidroksi ili C1-6 alkoksi u spoj s formulom I.
The pharmaceutical composition according to claim 30, characterized in that the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis or bone destruction accompanying cancer metastasis to bone. 
Farmaceutski pripravak za uporabu sukladno zahtjevu 17 ili 18, karakteriziran time što je abnormalni metabolizam kostiju osteoporoza, destrukcija kostiju koja prati reumatoidni artritis ili destrukcija kostiju koja prati metastaze raka u kostima.
The fractions containing the product were combined and evaporated to afforded the product as a white solid (0.0955 g, 51.5%). 
Frakcije koje sadrže proizvod su spojene i isparavane da bi se dobio proizvod kao bijela čvrsta supstanca (0.0955 g, 51.5%).
The present invention also relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. 
Vektor kloniranja ili ekspresije naznačen time da sadrži jednu ili više sekvenci DNK prema patentnom zahtjevu 4.
The method of claim 1 wherein said low levels of sICAM-1 means levels of fewer than 224 ng/ml. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-1 znače razine ispod 224 ng/ml.
The pharmaceutical composition of claim 1, wherein the micelle does not comprise a solid core. The pharmaceutical composition of claim 1, wherein the micelle coats a solid hydrophobic core. The pharmaceutical composition of claim 3, wherein the core comprises a traceable inorganic material selected from the group consisting of iron oxide, CdSe/CdS/ZnS, silver and gold. 
Farmaceutski sastav za uporabu u proizvodnji regulacijskih T-stanica specifičnih za najmanje jedan epitop T-stanice kod pojedinca, u liječenju ili prevenciji bolesti kod koje je obuzdavanje specifične imunološke reakcije blagotvorno, prema zahtjevu 3, naznačen time, da jezgra obuhvaća anorganski materijal koji se može pratiti, te koji je odabran iz skupine koju čine željezni oksid, CdSe/CdS/ZnS, srebro ili zlato.
decarboxylating a compound of Formula 3, or a salt thereof, or hydrolyzing and decarboxylating the compound of Formula 3 or a salt thereof, to yield a compound of Formula 8, or a salt thereof; 
dekarboksiliranju spoja Formule 3 [image] ili njegove soli, ili hidrolizi i dekarboksiliranju spoja Formule 3, ili njegove soli, kako bi se dobilo spoj Formule 8 [image] ili njegovu sol;
Table 1.- Test of vasorelaxation 
Tablica 1- Ispitivanje vazorelaksacije Spoj
The pharmaceutical composition of claim 7 further comprising at least one additional therapeutic agent. 
Farmaceutska smjesa prema zahtjevu 7 koja dalje sadrži barem jednu dodatnu terapijsku tvar.
The composition of Claim 5, wherein the fatty acid alkali or alkaline-earth metal salt is the sodium, calcium or potassium salt thereof. 
Pripravak prema zahtjevu 4, gdje je natrijeva, kalcijeva ili kalijeva sol C1-C10 masne kiseline natrijev butirat.
A syringe assembly 2 according to claim 1, wherein the engagement means 44 is disposed on an internal surface 42 of the outer sheath 6, preferably at least adjacent or towards the end 38 of the outer sheath 6, which is opposite to that from which medicament is dispensed, and/or wherein the engagement means 44 comprise screw threads. 
Set za špricu 2 prema zahtjevu 1, pri čemu se kopča 44 nalazi na vanjskoj površini 42 futrole 6, blizu ili uz onaj kraj 38 futrole 6, koji se nalazi nasuprot onome s kojeg se daje lijek, 1/1li pri čemu kopča 44 sadrži navoje.
The process of claim 1, wherein the main fuel composition and the fumigant are used for generating power using a compression ignition engine fuelled by the main fuel composition comprising methanol and water and not more than 20% dimethyl ether, the process further comprising: 
Postupak sukladno patentnom zahtjevu 1, naznačen time da glavna komponenta goriva i fumigant koriste za generiranje napajanja korištenjem motora s kompresijskim paljenjem koji kao gorivo koristi glavnu komponentu goriva koje sadrži metanol i vodu 1 ne više od 20% dimetil etera; taj postupak nadalje obuhvaća:
2: 482-489. An immunogenic composition comprising a stabilizing additive and a polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 4, wherein the polypeptide does not contain the first eighteen amino acids of SEQ ID NO: 1, and wherein the polypeptide has no cysteine residues. 
Polipeptid, naznačen time što sadrži aminokiselinski slijed s najmanje 99,5% istovjetnosti sa SEQ ID NO: 4, gdje je deletiran cisteinski ostatak odgovara položaju 4 u SEQ ID NO: 3, gdje polipeptid ne sadrži nikakve ostatke aminokiseline cisteina i dovesti do proizvodnje protutijela koja prepoznaju SEQ ID NO: 2.
ii) is capable of binding (auto)antibodies against the second extracellular loop (ECII) of B1-AR; and/or iii) is capable of inhibiting the interaction between B1-AR and (auto)antibodies against ECII of B1-AR. 
1i) se može vezati na (auto)protutijela protiv druge izvanstanične omče (EC) Bi-AR; i/ili ili) može inhibirati međudjelovanje između (B;-AR i (auto)protutijela protiv ECr B;1-AR.
The communication method according to claim 6, wherein the first frame configuration pattern and the second frame configuration pattern share at least one common transmission timing of an uplink subframe. 
Postupak komunikacije prema zahtjevu 5, naznačen time da prvi obrazac konfiguracije okvira za Primarnu Stanicu i drugi obrazac konfiguracije okvira za Sekundarnu Stanicu dijele barem jedno zajedničko vrijeme prijenosa podokvira uzlazne veze.
Process according to any of claims 1 to 7 wherein the composition comprises from 25 to 40 wt% of high density polyethylene post consumer resin relative to the total weight of the composition. 
Postupak prema bilo kojem zahtjevu od 1 do 7 naznačeno time da sastav sadrži od 0% 25 do 40 reciklirane polietilenske smole visoke gustoće u odnosu na ukupnu težinu sastava.
forming at least one space (5.1) by curving the inner side of at least one three-dimensional object (5), 
rezbarenje unutarnje strane navedenog transparentnog kamena (1), formirajući prostor i ostavljajući vanjsku ljusku (1.1),
A genetically modified mouse, wherein the genetic modification comprises a replacement of endogenous mouse genes encoding FcYRIIB, FcYRIII, and FcYRIV a-subunits with a gene encoding a human FcYRIIIA a-subunit, wherein the mouse expresses a human FcYRIIIA protein associated with an endogenous mouse FcR Y-subunit, wherein the human FcYRIIIA protein is expressed on the surface of a mouse NK cell. 
Genetski modificirani miš, naznačen time, što se genetska modifikacija sastoji od zamjene genomskog fragmenta endogenog mišjeg lokusa gena FcyR s niskim afinitetom, pri čemu se spomenuti genomski fragment sastoji od mišjih gena koji kodiraju FcyRIIB, FeyRIII 1 FeyRIV a-podjedinice, s humanim genomskim fragmentom koji kodira najmanje dva humana gena FcyR s niskim afinitetom, pri čemu najmanje dva humana gena FcyR s niskim afinitetom sadrže humanu FeyRIIA a-podjedinicu koja kodira gene, pri čemu miš izražava humani protein FeyRIIIA povezan s endogenom mišjom FcR y-podjedinicom, pri čemu se humani FcyRIIIA protein izražava na površini mišje NK stanice.
A combination for use in the treatment of diabetes mellitus type 2, the combination comprising 
Kombinacija namijenjena upotrebi u liječenju dijabetesa melitusa tip 2, naznačena time što se navedena kombinacija sastoji od
performing a stud welding action for each welding opening, wherein the welding pin is inserted into the welding opening, subsequently pushed through the underlying acoustic isolation layer, and pressed onto the metal surface of the first metal plate, in such a way that a welding current flows through the welding pin and the first metal plate, thereby melting and joining together the metal of the welding pin and the first metal plate by that welding current, which stud welding action is continued until the space between the welding pin and the welding opening at least for the most part is filled with molten metal of the welding pin and the first and/or second metal plate. 
- provođenju zavarivanja svornjaka za svaki otvor za zavarivanje, gdje se zatik za zavarivanje umetne u otvor za zavarivanje, zatim gurne kroz donji sloj zvučne izolacije, te pritisne na metalnu površinu prve metalne ploče, tako da struja zavarivanja prolazi kroz zatik za zavarivanje 1 prvu metalnu ploču, čime dolazi do taljenja i spajanja zajedno metala (8) zatika za zavarivanje i prve metalne ploče strujom zavarivanja, gdje se sa zavarivanjem svornjaka nastavi dok se prostor (9) između zatika za zavarivanje i otvor za zavarivanje ne ispuni rastaljenim metalom (10) zatika za zavarivanje 1 prve i/ili druge metalne ploča.
The polypeptide or polynucleotide of claim 1, further comprising administering one or more agents that enhance autophagy of the a-synuclein complexes or a polypeptide that enhances degradative processing of a-synuclein complexes within lysosomes. 
Primjena patentnog zahtjeva 1, koja dalje sadrži administraciju jednog ili više agenasa koji pojačavaju autofagiju a-sinukleinskih kompleksa, ili polipeptid koji pojačava process razlaganja a-sinukleinskih kompleksa unutar lizozoma.
A demountable pole dancing stage as claimed in claim 1, wherein each rotatable support member is mounted to the hub via a pair of collars and support arms, with the inner member of the support member pivotally mounted on the support arms of the collars via a rod. 
Sklopiva pozornica za ples na šipki iz zahtjeva 2 1 iz zahtjeva 3 ili 4, pri čemu je svaki rotirajući nosivi element montiran na središte pomoću para spojki i nosivog kraka, s tim da je unutarnja uspravna komponenta osovinski montirana na nosive krakove putem ravno izdignute šipke.
• a second tank (111) containing preheating liquid fluid and provided with a heater (R), in particular an electric resistor, to heat and maintain the temperature of the preheating fluid contained in it, 
drugi spremnik (111) koji sadrži tekućinu za prethodno zagrijavanje i koji ima grijač (R), posebno električni rezistor, za zagrijavanje i održavanje temperature u njemu sadržane tekućine za zagrijavanje,
In another embodiment, Z is -SH. 
Spoj prema zahtjevu 19, pri čemu Z je -OH ili -SH.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: Oxycodone hydrochloride: 10.0 mg/tablet Lactose (spray-dried): 69.25 mg/tablet 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje koji sadrži 10 mg oksikodon hidroklorida kada je testiran u komparativnoj kliničkoj studiji je bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži: a) Oksikodon hidroklorid: 10.0 mg/tableti b) Laktoza (suho raspršena): 69.25 mg/tableti 6) Povidon: 5,0 mg/tableti d) Eudragit" RS 30D (krutine); 10.0 mg/tableti
The system of claim 1 further comprising a safety pressure outlet (20D) to relieve pressure from said chamber when said pressure exceeds a predefined pressure level. 
Sustav prema zahtjevu 1, naznačen time, da nadalje sadrži sigurnosni izlazni tlak (20D) za oslobađanje tlaka iz navedene komore kada navedeni tlak prelazi unaprijed definiranu razinu tlaka.
The probe of claim 1, wherein the exposed portion (19) extends beyond the distal end (20) of the cannula (18) a distance of approximately 3.0 millimeters to 8.0 millimeters. 
Sonda prema zahljevu 1, naznačena time, da se izloženi dio (19) proteže izvan udaljenog kraja (29) kanile (18) na udaljenosti od otprilike 3,0 do 8,0 milimetara.
wherein the secondary upper surface (10od) has a minimum horizontal area EPMATHMARKEREP and a maximum horizontal area EPMATHMARKEREP wherein r = radius of the ladle bottom and r ≥ 0,75 m with rmax =2m for all ladle bottoms with an effective radius of ≥ 2m, 
dok sekundama gornja površina (10od) ima minimalno horizontalno područje [image] i maksimalno horizontalno područje [image] gdje r = radijus dna grabilice i r > 0,75 m s rmax = 2 m za sva dna grabilica s efektivnim radijusom od > 2 m,
The pharmaceutical composition or dosage form of any one of claims 1 to 15 for use in a method of improving short and long term growth and nutritional outcomes of a newborn or infant with symptomatic or confirmed pancreatic insufficiency. 
Kompozicija ili dozna forma u skladu sa zahtjevima 1 do 13, za primjenu u postupcima kratkoročnog i dugoročnog poboljšanja rasta i ishoda ishrane kod novorođenčadi ili dojenčadi sa simptomatskom ili potvrđenom insuficijencijom pankreasa.
The cartridge of claim 3 wherein the byte includes at least four bits identifying the access mode of the at least one of the data field grouping. 
Patrona (24) u skladu s patentnim zahtjevom 3, naznačena time što bajt sadrži najmanje četiri bita koji identificiraju pristupni način za najmanje jednu od grupacija podatkovnih polja.
A lipid compound according to claim 11, wherein the compound is present in the form of its R enantiomer at the carbon attached to (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy, R2, R3, and X. 
Lipidni spoj prema zahtjevu 11, pri čemu je spoj prisutan u obliku svog R enantiomera na ugljiku vezanom na (52,82,112,142,177)-ikoza-5,8,11,14,17-pentaen-1-iloksi, R>, R3 i X.
To further illustrate the invention, without limitation, the following embodiments of formula IA are within the scope of the invention, in particular for the compounds as the free base or salt thereof: 
Kako bi se dalje ilustrirao izum bez da ga se ograniči, slijedeći oblici formule IA su unutar dometa izuma pogotovo glede spojeva kao slobodnih baza i njihovih soli:
H-Asp(O-P2)-Trp-Pro-OH through attachment of the Gly residue of the 2-3 eptifibatide fragment to the Asp residue of the 4-6 eptifibatide fragment, thereby forming the 2-6 eptifibatide fragment. 
H-Asp(O-P>)-Trp-Pro-OH spajanjem rezidua Gly fragmenta 2-3 eptifibatida na reziđduum Asp fragmenta 4-6 eptifibatida, čime se formira fragment 2-6 eptifibatida
and providing a gas flow-line from the off-gas separation section of the melamine production zone to the condensation system, wherein said condensation system is configured for subjecting the vapor from the liquid/gas separation section of the urea plant and the melamine off-gas to combined condensation in indirect heat exchange with the aqueous urea stream. A method of increasing the plant capacity of the melamine production zone of a pre-existing facility for the integrated production of urea and melamine, said facility comprising a urea production zone and a melamine production zone; 
- linija za protok plina od dijela za odvajanje ispušnih plinova u sklopu zone za proizvodnju melamina do kondenzacijskog sustava, pri čemu je kondenzacijski sustav konfiguriran za obradu pare iz dijela za odvajanje HR P20190746 T1 tekućine/plina u sklopu pogona za proizvodnju uree i ispušnih plinova melamina putem kombinirane kondenzacije u neizravnoj izmjeni topline s vodenim mlazom uree.
A method for fixing profiles (2) according to claim 10, characterized in that the fixing operations of the fastening element (4) into the settlement profile as well as of the fastening element (4) into the profile (2) are accomplished by pressure fitting. 
Postupak za učvršćivanje profila (2) prema zahtjevu 9, naznačen time da se operacije učvršćivanja elementa za učvršćivanje (4) u ugradbeni profil kao i elementa za učvršćivanje (4) u profile (2) postižu pomoću postavljanja pritiskom.
In some embodiments the invention relates to a process of producing a granule comprising a GLP-1 peptide, wherein the process comprises the steps: a) mixing a GLP-1 peptide, optionally a filler and/or a binder; and b) roller compacting the mixture of step a. 
Postupak proizvodnje farmaceutskog pripravka koji sadrži sol N-(8-(2-hidroksibenzoiljamino)kaprilne kiseline i GLP-1 peptid, naznačen time što se postupak sastoji u koracima: a) = miješanja GLP-1 peptida s punilom i/ili vezivom; b) suhog granuliranja smjese iz koraka a;
The transfer vehicle of the invention is a liposornal vesicle, to facilitate the transfer of a nucleic acid to target cells and tissues. 
Nosač transfera prema bilo kojem od zahtjeva 2 do 7, naznačen time što nosač transfera inkapsulira nukleinsku kiselinu ili protein.
The use according to claim 8, wherein the δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative is a compound of formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 8, naznačena time, da derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
The method of claim 1, wherein the pharmaceutically acceptable oil is present in a concentration of about 0.1% to about 10% by total weight of the ring. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da su farmaceutski prihvatljiv ugljikovodik ili glicerolni esteri masnih kiselina prisutni u koncentraciji od 0,1 % do 10 % ukupne mase prstena.
To the inverting and non-inverting inputs of amplifier 90 there are connected, respectively, the series of a resistor 82 and a decoupling capacitor 83, and a resistor 84. 
Na invertirajući i neinvertirajući ulaz pojačala 90, spojeni su: serijski spojeni otpornik 82 i rastavni kondenzator 83, i otpornik 84.
The system of claim 1 wherein biasing electrodes includes one or more of one or more point electrodes positioned within the containment chamber to contact open field lines, a set of annular electrodes between the confinement chamber and the first and second formation sections to charge far-edge flux layers in an azimuthally symmetric fashion, a plurality of concentric stacked electrodes positioned in the first and second divertors to charge multiple concentric flux layers, and anodes of the plasma guns to intercept open flux. 
Postupak prema zahtjevu 1, 4 do 5 1 7, naznačen time, da prednaponske elektrode obuhvaćaju jednu ili više od jedne ili više točkastih elektroda pozicioniranih unutar priključne komore, u svrhu doticaja s linijama otvorenog polja, komplet prstenastih elektroda između priključne komore i prvog i drugog tvorbenog dijela, u svrhu punjenja